Dutasteride/tamsulosin

Dutasteride/tamsulosin
Combination of
Dutasteride	5α-Reductase inhibitor
Tamsulosin	Alpha-1 blocker
Clinical data
Trade names	Jalyn
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Dutasteride_and_tamsulosin;
Pregnancy; category	AU: X (High risk); ;
Routes of; administration	By mouth
ATC code	G04CA52 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Identifiers
CAS Number	2227979-41-9;
KEGG	D11389;

Dutasteride/tamsulosin, sold under the brand name Jalyn among others, is a medication produced by GlaxoSmithKline for the treatment of adult male symptomatic benign prostatic hyperplasia (BPH).^[3] It is a combination of two previously existing medications: dutasteride, brand name Avodart, and tamsulosin, brand name Flomax. It contains 0.5 mg of dutasteride and 0.4 mg of tamsulosin hydrochloride.^[2]

Jalyn was the result of the CombAT (Combination of Avodart and Tamsulosin) trial of 2008. It was approved by the U.S. Food and Drug Administration (FDA) on June 14, 2010.^[4] In June 2011, the FDA approved a label change to warn of "Increased Risk of High-grade Prostate Cancer" from Jalyn.^[5]

References

^ https://www.tga.gov.au/resources/prescription-medicines-registrations/dutalosin-ksj-pharmatech
^ ^a ^b "Jalyn - dutasteride and tamsulosin hydrochloride capsule". DailyMed. U.S. National Library of Medicine. Retrieved 28 December 2020.
^ Keating GM (May 2012). "Dutasteride/tamsulosin: in benign prostatic hyperplasia". Drugs & Aging. 29 (5): 405–19. doi:10.2165/11208920-000000000-00000. PMID 22550968. S2CID 209142875.
^ "Approval Package for: Dutasteride 0.5 mg/Tamsulosin hydrochloride 0.4 mg" (PDF). Center for Drug Evaluation and Research. Food and Drug Administration. 14 June 2010.
^ "Detailed View: Safety Labeling Changes: Jalyn (dutasteride and tamsulosin) capsules". Center for Drug Evaluation and Research. U.S. Food and Drug Administration. June 2011. Archived from the original on 6 January 2012.